Promising Trial Data for ONWARD Spinal Cord Stimulation

Image credit: ONWARD Medical

ONWARD Medical, a medtech specialising in nerve stimulation therapies for restoring limb movement following spinal cord injury (SCI), has announced positive findings from its global pivotal trial for its ARC-EX Therapy device.

Published last month in Nature Medicine, trial data showed all primary safety and effectiveness endpoints were achieved for helping improve SCI patients’ hand and arm function with use of ONWARD’s ARC-EX Therapy.

More than 70 percent of the 65 study participants demonstrated response to the therapy based on criteria relating to improvements to both strength and function.

That figure rose to 90 percent of participants when looking at those who showed improvement in at least one strength or functional outcome.

“Improvement in arm and hand function is among the highest priorities for people with tetraplegia who have endured far too long without effective therapies for functional recovery,” said ONWARD Medical CEO, Dave Marver in a statement.

“The findings published in Nature Medicine provide critical and compelling evidence that ARC-EX has the potential to restore independence in daily activities and improve quality of life.”

ONWARD Medical submitted ARC-EX Therapy to the US Food and Drug Administration (FDA) for approval in April, with plans to also make a European submission.

Refer to the research published via Nature Medicine or the full press release from ONWARD Medical for more information.